Mesothelioma

• 

  Subject Areas on Research

  • 18F-fluoro-2-deoxy-D-glucose positron emission tomography and positron emission tomography/computed tomography imaging of malignant pleural mesothelioma. 
  • A Proposed System Toward Standardizing Surgical-Based Treatments for Malignant Pleural Mesothelioma, From the Joint National Cancer Institute-International Association for the Study of Lung Cancer-Mesothelioma Applied Research Foundation Taskforce. 
  • A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307. 
  • A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. 
  • A review of chemotherapy trials for malignant mesothelioma. 
  • A somatic TSHR mutation in a patient with lung adenocarcinoma with bronchioloalveolar carcinoma, coronary artery disease and severe chronic obstructive pulmonary disease. 
  • Advances in occupational health. 
  • Amphiboles and chrysotile asbestos exposure. 
  • An Investigation of Cancer-Directed Surgery for Different Histologic Subtypes of Malignant Pleural Mesothelioma. 
  • Asbestos Fiber Concentrations in the Lungs of Brake Repair Workers: An Updated Analysis Using Several Regression Methods to Handle Nondetectable Measurements. 
  • Asbestos bodies in pulmonary hilar lymph nodes. 
  • Asbestos content of lung tissue in asbestos associated diseases: a study of 110 cases. 
  • Asbestos content of lung tissue in patients with malignant peritoneal mesothelioma: A study of 42 cases. 
  • Asbestos fiber type in malignant mesothelioma: an analytical scanning electron microscopic study of 94 cases. 
  • Asbestos, asbestosis, and cancer: the Helsinki criteria for diagnosis and attribution. 
  • Asbestos-related disease associated with exposure to asbestiform tremolite. 
  • Autocrine growth stimulation by transforming growth factor alpha in asbestos-transformed rat mesothelial cells. 
  • BAP1 Tumor Predisposition Syndrome Presenting as a Recurrent Ovarian Sex Cord-Stromal Tumor. 
  • CT for detection of malignant posterior intercostal lymph nodes in patients undergoing pre-operative staging for malignant pleural mesothelioma. 
  • Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807). 
  • Cardiac tamponade complicating trimodal therapy for malignant mesothelioma. 
  • Characterization of platelet-derived growth factor and platelet-derived growth factor receptor expression in asbestos-induced rat mesothelioma. 
  • Chemotherapy in malignant pleural mesothelioma. A review. 
  • Comparison of monoclonal versus polyclonal calretinin antibodies for immunohistochemical diagnosis of malignant mesothelioma. 
  • Comparison of pulmonary and pleural responses of rats and hamsters to inhaled refractory ceramic fibers. 
  • Comprehensive Molecular and Pathologic Evaluation of Transitional Mesothelioma Assisted by Deep Learning Approach: A Multi-Institutional Study of the International Mesothelioma Panel from the MESOPATH Reference Center. 
  • Congenital endodermal heterotopia of the atrioventricular node: evidence for the endodermal origin of so-called mesotheliomas of the atrioventricular node. 
  • Crocidolite and mesothelioma. 
  • Curative resection of a well-differentiated papillary mesothelioma of the pericardium. 
  • Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. 
  • Current treatment options and biology of peritoneal mesothelioma: meeting summary of the first NIH peritoneal mesothelioma conference. 
  • Dataset for Reporting of Malignant Mesothelioma of the Pleura or Peritoneum: Recommendations From the International Collaboration on Cancer Reporting (ICCR). 
  • Diagnosis of diffuse malignant mesothelioma: experience of a US/Canadian Mesothelioma Panel. 
  • Diffuse adenomatoid tumor of the uterus with a serosal papillary cystic component. 
  • Diffuse malignant mesothelioma and synchronous lung cancer: A clinicopathological study of 18 cases. 
  • Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. 
  • Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer and Leukemia Group B. 
  • Disruption of iron homeostasis in mesothelial cells after talc pleurodesis. 
  • EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach. 
  • Edatrexate (10-ethyl-deaza-aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma. Sequential phase II trials by the cancer and leukemia group B. 
  • Effect of erionite on the pleural mesothelium of the Fischer 344 rat. 
  • Effect of fibrous glass on rat pleural mesothelium. Histopathologic observations. 
  • Effect of increasing experience on dosimetric and clinical outcomes in the management of malignant pleural mesothelioma with intensity-modulated radiation therapy. 
  • Endoscopic ultrasound-guided fine needle aspiration is useful for nodal staging in patients with pleural mesothelioma. 
  • Environmental asbestos contamination: What are the risks? 
  • Environmental malignant mesothelioma in southern Anatolia: a study of fifty cases. 
  • Epidemiology of asbestos-related diseases. 
  • Exposure to brake dust and malignant mesothelioma: a study of 10 cases with mineral fiber analyses. 
  • Expression of insulin-like growth factor II in spontaneously immortalized rat mesothelial and spontaneous mesothelioma cells: a potential autocrine role of insulin-like growth factor II. 
  • Expression of telomerase reverse transcriptase (TERT) in malignant mesotheliomas. 
  • Extended surgical staging for potentially resectable malignant pleural mesothelioma. 
  • Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients. 
  • FDG PET/CT for Primary Staging of Lung Cancer and Mesothelioma. 
  • FDG PET/CT in the management of primary pleural tumors and pleural metastases. 
  • Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. 
  • Fiber analysis vignettes: Electron microscopy to the rescue! 
  • Fiber potency vs. importance. 
  • Fibrous glass and cancer. 
  • First somatic mutation of E2F1 in a critical DNA binding residue discovered in well-differentiated papillary mesothelioma of the peritoneum. 
  • First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743. 
  • Follow-up study of chrysotile asbestos textile workers: cohort mortality and case-control analyses. 
  • Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. 
  • Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B. 
  • Global and regional burden of cancer in 2016 arising from occupational exposure to selected carcinogens: a systematic analysis for the Global Burden of Disease Study 2016. 
  • Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group. 
  • Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. 
  • Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. 
  • High-dose doxorubicin, dexrazoxane, and GM-CSF in malignant mesothelioma: a phase II study-Cancer and Leukemia Group B 9631. 
  • High-dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase II study 9234. 
  • Higher doses of alpha-interferon do not increase the activity of the weekly cisplatin-interferon combination in advanced malignant mesothelioma. 
  • Human disease consequences of fiber exposures: a review of human lung pathology and fiber burden data. 
  • Immunohistochemical analysis of the p16INK4 cyclin-dependent kinase inhibitor in malignant mesothelioma. 
  • Immunohistochemical differentiation of sarcomatoid mesotheliomas from other spindle cell neoplasms. 
  • Impact of Age on Long-Term Outcomes of Surgery for Malignant Pleural Mesothelioma. 
  • Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database. 
  • In Reply to "Malignant Mesothelioma and Its Nonasbestos Causes". 
  • Integrative Molecular Characterization of Malignant Pleural Mesothelioma. 
  • Intensity-modulated radiotherapy for resected mesothelioma: the Duke experience. 
  • Intrapleural cisplatin and mitomycin for malignant mesothelioma following pleurectomy: pharmacokinetic studies. 
  • Invited commentary. 
  • Irinotecan for malignant mesothelioma A phase II trial by the Cancer and Leukemia Group B. 
  • Laparoscopy and mesothelioma. 
  • Localized malignant mesothelioma. 
  • Lung cancer mortality among asbestos textile workers: a review and update. 
  • Lung cancer mortality and fibre exposures among North Carolina asbestos textile workers. 
  • Lymphangitic carcinomatosis: A common radiographic manifestation of local failure following extended pleurectomy/decortication in patients with malignant pleural mesothelioma. 
  • Malignant (Diffuse) Mesothelioma in Patients With Hematologic Malignancies: A Clinicopathologic Study of 45 Cases. 
  • Malignant Diffuse Mesothelioma in Women: A Study of 354 Cases. 
  • Malignant Mesothelioma and Its Non-Asbestos Causes. 
  • Malignant Mesothelioma in Individuals With Nonmesothelial Neoplasms. 
  • Malignant mesothelioma and duration of asbestos exposure: correlation with tissue mineral fibre content. 
  • Malignant mesothelioma and occupational exposure to asbestos: a clinicopathological correlation of 1445 cases. 
  • Malignant mesothelioma associated with low pulmonary tissue asbestos burdens: a light and scanning electron microscopic analysis of 18 cases. 
  • Malignant mesothelioma diagnosed at a younger age is associated with heavier asbestos exposure. 
  • Malignant mesothelioma in the jewelry industry. 
  • Malignant mesothelioma in women. 
  • Malignant mesothelioma not related to asbestos exposure: Analytical scanning electron microscopic analysis of 83 cases and comparison with 442 asbestos-related cases. 
  • Malignant mesothelioma with heterologous elements: clinicopathological correlation of 27 cases and literature review. 
  • Malignant peritoneal mesothelioma and Crohn disease. 
  • Malignant peritoneal mesothelioma in patients with endometriosis. 
  • Malignant pleural mesothelioma and the Society of Thoracic Surgeons Database: an analysis of surgical morbidity and mortality. 
  • Malignant pleural mesothelioma. 
  • Malignant pleural mesothelioma: value of CT and MR imaging in predicting resectability. 
  • Measuring EMPs in the lung what can be measured in the lung: Asbestiform minerals and cleavage fragments. 
  • Mesothelioma in the age of "Omics": Before and after The Cancer Genome Atlas. 
  • Mesothelioma of the tunica vaginalis testis. 
  • Mesothelioma vs. adenocarcinoma. 
  • Mesotheliomas induced in rats by the fibrous mineral erionite are independent from p53 alterations. 
  • Mineral fiber content of lung tissue in patients with environmental exposures: household contacts vs. building occupants. 
  • Mineralogy of asbestos. 
  • Molecular Analysis of a Patient With Neurofibromatosis 2 (NF2) and Peritoneal Malignant Mesothelioma. 
  • Mortality among sheet metal workers participating in a respiratory screening program. 
  • NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016. 
  • New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi-Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center. 
  • Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study. 
  • Occupational asbestos exposure and the incidence of non-Hodgkin lymphoma of the gastrointestinal tract: an ecologic study. 
  • Pathologic Considerations and Standardization in Mesothelioma Clinical Trials. 
  • Pathologic quiz case: a 53-year-old man with chest pain and cough. Malignant (diffuse) pleural mesothelioma, biphasic variant, with heterologous differentiation. 
  • Pathology of human mesothelioma. Etiologic and diagnostic considerations. 
  • Pericardial mesothelioma after exposure to asbestos. 
  • Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Müllerian carcinoma, gastrointestinal primary malignancies, and mesothelioma. 
  • Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report. 
  • Pleural malignant mesothelioma following Wilms' tumor. 
  • Possible cellular and molecular mechanisms for asbestos carcinogenicity. 
  • Product liability forecasting for asbestos-related personal injury claims: a multidisciplinary approach. 
  • Pulmonary asbestos body counts and electron probe analysis of asbestos body cores in patients with mesothelioma: a study of 25 cases. 
  • Quantifying the dosimetric trade-offs when using intensity-modulated radiotherapy to treat concave targets containing normal tissues. 
  • Quantitative and analytical studies in the diagnosis of mesothelioma. 
  • RE: Asbestos in brakes: exposure and risk of disease. 
  • Radiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee - International Association for the Study of Lung Cancer - Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting. 
  • Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B. 
  • Re-expression of p16INK4a in mesothelioma cells results in cell cycle arrest, cell death, tumor suppression and tumor regression. 
  • Recommendations for the reporting of pleural mesothelioma. 
  • Recommendations for the reporting of pleural mesothelioma. 
  • Recommendations for the reporting of pleural mesothelioma. 
  • Renal cell carcinoma development in the rat independent of alterations at the VHL gene locus. 
  • Response to comments on 'Malignant mesothelioma diagnosed at a younger age is associated with heavier asbestos exposure' by Farioli et al. and Oddone et al. 
  • Response to comments on 'Malignant mesothelioma diagnosed at a younger age is associated with heavier asbestos exposure' by Farioli et al. and Oddone et al. 
  • Response to letter regarding "Talc and mesothelioma: mineral fiber analysis of 65 cases with clinicopathological correlation". 
  • Response to the methylation inhibitor dihydro-5-azacytidine in mesothelioma is not associated with methylation of p16INK4a: results of cancer and leukemia group B 159904. 
  • Review and update of uncommon primary pleural tumors: a practical approach to diagnosis. 
  • Role of closed-needle biopsy in the diagnosis of malignant mesothelioma of the pleura. 
  • Salud Ocupacional. 
  • Salud ocupacional. 
  • Sarcomatoid Peritoneal Mesothelioma: Clinicopathologic Correlation of 13 Cases. 
  • Sarcomatoid mesothelioma: a clinical-pathologic correlation of 326 cases. 
  • Science to practice: Molecular targeting with SPECT/CT and MR imaging in oncology--integration of functional and structural imaging. 
  • Serum soluble mesothelin-related protein (SMRP) and fibulin-3 levels correlate with baseline malignant pleural mesothelioma (MPM) tumor volumes but are not useful as biomarkers of response in an immunotherapy trial. 
  • Silica-induced pleural disease: an unusual case mimicking malignant mesothelioma. 
  • Strike or Spare? A Review of Lung-Sparing Therapies for Malignant Pleural Mesothelioma. 
  • Surprising finding of a primary pericardial mesothelioma. 
  • Talc should not be used for pleurodesis in patients with nonmalignant pleural effusions. 
  • The 2015 World Health Organization Classification of Tumors of the Pleura: Advances since the 2004 Classification. 
  • The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 Classification. 
  • The Chicago Consensus on Peritoneal Surface Malignancies: Management of Peritoneal Mesothelioma. 
  • The Chicago Consensus on peritoneal surface malignancies: Management of peritoneal mesothelioma. 
  • The Impact of Adjuvant Hemithoracic Radiation on Outcomes in Patients With Stage I-III Malignant Pleural Mesothelioma: A Dual Registry Analysis. 
  • The Use of Radiation Therapy for the Treatment of Malignant Pleural Mesothelioma: Expert Opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. 
  • The diagnosis of desmoplastic malignant mesothelioma and its distinction from fibrous pleurisy: a histologic and immunohistochemical analysis of 31 cases including p53 immunostaining. 
  • The diagnostic distinction between malignant mesothelioma of the pleura and adenocarcinoma of the lung as defined by a monoclonal antibody (B72.3). 
  • The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell/pleomorphic (sarcomatoid) carcinomas of the lung: evidence-based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center. 
  • The fake fat phenomenon in organizing pleuritis: a source of confusion with desmoplastic malignant mesotheliomas. 
  • The proposed new international TNM staging system for malignant pleural mesothelioma: application to imaging. 
  • The role of analytical SEM in the determination of causation in malignant mesothelioma. 
  • The role of imaging in malignant pleural mesothelioma. 
  • The role of smoking and exposure to asbestos and man-made vitreous fibers in a questionable case of mesothelioma. 
  • The separation of benign and malignant mesothelial proliferations. 
  • Transforming growth factor alpha and epidermal growth factor receptor in reactive and malignant mesothelial proliferations. 
  • Tremolite and mesothelioma. 
  • Trimetrexate in malignant mesothelioma: A Cancer and Leukemia Group B Phase II study. 
  • Trisomy of rat chromosome 1 associated with mesothelial cell transformation. 
  • Twenty-five years of fiber analysis: what have we learned? 
  • Ultrastructural features of diffuse malignant mesotheliomas. 
  • Utility of integrated computed tomography-positron emission tomography for selection of operable malignant pleural mesothelioma. 
  • Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials. 
  • Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107). 
  • Well-differentiated papillary mesothelioma. 
  • Wilms' tumor suppressor gene expression in rat and human mesothelioma. 
• 

  Keywords of People

  • Dement, John McCray, Professor Emeritus in Family Medicine and Community Health, Family Medicine & Community Health,Occupational & Environmental Medicine
  • Pang, Herbert, Adjunct Assistant Professor in the Department of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics
  • Patz Jr., Edward F., James and Alice Chen Distinguished Professor of Radiology, Pathology
  • Tong, Betty Caroline, Associate Professor of Surgery, Surgery, Cardiovascular and Thoracic Surgery
  • Yoo, Sua, Associate Professor of Radiation Oncology, Radiation Oncology